Merck has initiated the pivotal, phase 3 waveLINE-010 trial to evaluate Zilovertamab vedotin, an investigational ADC, in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for previously untreated diffuse large B-cell lymphoma

waveLINE-010 is a global, randomized, open-label trial enrolling approximately 1,046 patients, with progression-free survival as the primary endpoint

The trial aims to compare the efficacy of Zilovertamab vedotin plus R-CHP against the standard R-CHOP regimen, targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)

Following positive results from the Phase 2 waveLINE-007 trial, Merck continues its research to assess the potential benefits of ADCs in treating aggressive hematologic malignancies

Zilovertamab vedotin is also being investigated in the Phase 2/3 waveLINE-003 and Phase 2 waveLINE-007 trials, with recent data presented at the 66^th ASH, 2024